Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785226 · ClinicalTrials.gov registry record · Phase 1
RDEA119 and Sorafenib Combination Dose Escalation Study
A Phase 1 study of Advanced Cancer, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 10
- Study locations
NCT00785226: Completed Phase 1 study of Advanced Cancer, sponsored by Bayer.
NCT00785226 is a Phase 1 study of Advanced Cancer that has completed, run by Bayer. The registered enrollment target is 62 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00785226, a Phase 1 study of Advanced Cancer, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1/2 dose escalation study to investigate the combination of RDEA119 and sorafenib in advanced cancer patients.
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG RDEA119
Study Locations (10)
New York
- New York Oncology Hematology, PC - Albany
- Roswell Park Cancer Institute - Buffalo
- James P. Wilmot Cancer Center - Rochester
Texas
- Texas Oncology - Baylor Charles A. Simmons Cancer Center - Dallas
- Texas Oncology-Tyler - Tyler
California
- USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center - Los Angeles
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Pennsylvania
- UPenn - Philadelphia
South Carolina
- Greenville Hospital System University Medical Center, (ITOR) - Greenville
Ontario
- Toronto General Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT00785226 record still lists
NCT00785226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib is the first listed.
NCT00785226 lists 10 locations in 7 states (New York, Texas, California).
Frequently Asked Questions
What is clinical trial NCT00785226 about?
NCT00785226 is a clinical study titled "RDEA119 and Sorafenib Combination Dose Escalation Study". Phase 1/2 dose escalation study to investigate the combination of RDEA119 and sorafenib in advanced cancer patients.
What is the current status of trial NCT00785226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2008-11. Estimated completion is 2012-04.
What conditions does trial NCT00785226 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00785226?
The interventions under investigation include: Sorafenib (DRUG), RDEA119 (DRUG).
Who is sponsoring clinical trial NCT00785226?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00785226 being conducted?
This trial has 10 study locations across California, Nevada, New York, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00785226's enrollment target sits among peer trials
62 78th of 122 higher than 45 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia